Mucopolysaccharidosis (MPS) Treatment Market

Introduction

Mucopolysaccharidosis (MPS) is a group of rare, hereditary and incurable “storage diseases.” In MPS the mucopolysaccharides (sugar bound proteins) are not broken down correctly which causes products of incomplete metabolism to accumulate in the body. In MPS and other storage diseases, metabolic products that have not been eliminated have an impact on the functioning of cells, tissues and organs. The products typically accumulate, and cause symptoms, in different parts of the body.

One in 25,000 births, is estimated to be the prevalence of all forms of mucopolysaccharidosis. However, mucopolysaccharidoses, especially the milder forms of the diseases are often unrecognized, these disorders are under-diagnosed or misdiagnosed which makes it difficult to determine their true frequency in the general population.

Mucopolysaccharidosis (MPS) Treatment Market: Drivers and Restraints

Increase in no. of people suffering from lysosomal diseases and high burden of rare diseases   are expected to be the critical factors that may fuel the growth of the mucopolysaccharidosis (MPS) treatment market. The growing awareness regarding the novel therapies to treat mucopolysaccharidosis may boost the growth of mucopolysaccharidosis (MPS) treatment market. Moreover, the rise in research and development activities by key players for new therapeutics may also drive the growth of the market.  Additionally, the growing unmet clinical needs of patients along with better treatment outcomes may also help the mucopolysaccharidosis (MPS) treatment market to grow significantly.

However, complications and severity involved in the treatment of mucopolysaccharidosis (MPS) may hamper the growth of mucopolysaccharidosis (MPS) treatment market. High cost involved in the available treatment and lack of awareness among the rural population in underdeveloped and developing countries may also result in hindering the growth of mucopolysaccharidosis (MPS) treatment market. Another factor that may restrain the growth of mucopolysaccharidosis (MPS) treatment market is the delay associated with the diagnosis of mucopolysaccharidosis.

Mucopolysaccharidosis (MPS) Treatment Market: Segmentation

Based on disease type	Mucopolysaccharidosis (MPS) type I Mucopolysaccharidosis (MPS) type II Mucopolysaccharidosis  (MPS) type VI Mucopolysaccharidosis (MPS) type IV A others
Based on therapy type	Enzyme replacement therapy Stem cell therapy
Based on distribution channel	Retail pharmacies Hospital pharmacies Online pharmacies

 

Mucopolysaccharidosis (MPS) Treatment Market: Overview

In the disease type segment, Mucopolysaccharidosis (MPS) type I also known as hurler’s syndrome is one of the most severe type and has a higher presence among the population compared to other types.

In the therapy type segment, the mucopolysachharidosis (MPS) treatmement market is segmented into stem cell therapy and enzyme replacement therapy.

In this distribution channel segment, Retail pharmacies may dominate the market in terms of revenue but online pharmacies are expected to experience substantial growth during the forecast period due to the growing technological developments and increasing focus on convenience.

Mucopolysaccharidosis (MPS) Treatment Market: Regional-Wise Outlook

Geographically, the global mucopolysaccharidosis (MPS) treatment market is segmented into  5 regions, which is, North America, Latin America, Asia Pacific, Europe and Middle East & Africa.  

North America is expected to dominate the global market for mucopolysaccharidosis treatment during the forecast period. This can be attributed because of growing awareness among patient population regarding the advanced treatment options. Additionally, the presence of significant players and biopharmaceutical companies along with ongoing clinical trials may also drive the growth of mucopolysaccharidosis (MPS) treatment market.  

Europe is expected to have the 2nd largest market for mucopolysaccharidosis (MPS) treatment. However, Asia Pacific is expected experience significant market growth during the forecast periods as a result of untapped opportunities in this region. Moreover, the launch of novel therapeutics and the rising patient population may also boost the growth of mucopolysaccharidosis (MPS) treatment market in this region.

Mucopolysaccharidosis (MPS) Treatment Market: Key Players

Some of the players identified in the mucopolysaccharidosis (MPS) treatment market include:

• Sanofi
• F. Hoffmann-La Roche Ltd
• Lupin
• DAIICHI SANKYO COMPANY LTD.
• Pfizer Inc
• Bayer AG
• Cipla Inc.
• Biomarin
• CENTOGENE AG

The report covers exhaustive analysis on:

• Mucopolysaccharidosis (MPS) Treatment Market Segments
• Mucopolysaccharidosis (MPS) Treatment Market Dynamics
• Historical Actual Market Size, 2013 - 2017
• Mucopolysaccharidosis (MPS) Treatment Market Size & Forecast 2018 to 2024
• Market Current Trends/Issues/Challenges
• Competition & Companies involved
• Market Drivers and Restraints

Regional analysis includes

• North America
• Latin America
• Europe
• Asia Pacific
• Middle East & Africa

Report Highlights:

• Shifting Industry dynamics
• In-depth market segmentation
• Historical, current and projected industry size recent industry trends
• Key Competition landscape
• Strategies for key players and product offerings
• Potential and niche segments/regions exhibiting promising growth
• A neutral perspective towards market performance

To know more about delivery timeline for this report Contact Sales